1. Introduction {#s0005}
===============

Multiple myeloma (MM) is an incurable cancer of plasma cells, caused by aberrant expansion of monoclonal plasma B cells in the bone marrow [@bib1]. MM accounts for 10% of all hematological cancers, and is characterized by wide clinical and pathophysiologic heterogeneities, with lethal outcomes. The median survival time of MM patients is 7--8 years [@bib2]. Thus, a better understanding of MM biology will aid in developing new therapeutic modalities that could potentially cure MM.

Many advances in the understanding of MM pathogenesis have been the result of major developments in genomic technologies [@bib3], [@bib4]. In recent years, genomic technologies identified certain disease-related biomarkers [@bib5], [@bib6]. For example, Leone et al. [@bib7] have demonstrated that *CDKN2C* plays an important role in the progression and clinical outcome of MM. Jagani et al. [@bib8] have indicated that *Bmi-1* is crucial for MM growth. However, the reproducibility and overlap of the extracted genes are poor. Generally, gene biomarkers obtained from gene-based classification methods are often produced independently. Due to this, the gene signatures might not synergistically improve the overall classification ability.

In an attempt to overcome these shortcomings, it is important to understand the complicated interactions between genes, to help elucidate essential principles of cellular systems and the disease machinery [@bib9]. To obtain a clear interpretation of genomic results, pathway analysis is the first criteria to identify abnormal pathways, to shed light on the potential biology of genes, thereby decreasing complexity and promoting explanatory power [@bib10]. Moreover, several studies have reported that pathways-based classifiers are more reproducible and usually achieve better results, as compared to the single gene biomarkers-based classifier [@bib11].

Remarkably, more than one pathway is involved in the development of cancer and its progression, due to the complex characterization of biological systems. Two or more pathways may be interconnected to further affect the disease onset, as functional proteins might participate in multiple pathways [@bib12]. Therefore, identifying cross-talk between pathways is important to understand the molecular mechanisms of MM. Intuitively, different pathways influence each other, but at present, there is no reliable method to quantify the amount of cross-talk between paired pathways [@bib13]. An integrative approach using Monte Carlo cross-validation has been created, to quantify the cross-talk between paired pathways.

Therefore, this study considers gene expression profile and biological pathway data as study objects, and utilizes Monte Carlo cross-validation analysis to detect pathway cross-talk in MM. The pathway cross-talk may be potential signatures for early detection and treatment of MM.

2. Materials and methods {#s0010}
========================

The integrative approach using Monte Carlo cross-validation method comprised of four steps: Firstly, identification of differentially expressed genes (DEGs) between MM and healthy control samples was conducted. Secondly, the DEGs obtained were mapped to the pathways downloaded from the database of ingenuity pathways analysis (IPA), to reveal the relationship between DEGs and pathways enriched by these DEGs. A subset of pathways enriched by DEGs were also required. Thirdly, a discriminating score (DS) value for each pair of pathways was computed. Lastly, random forest (RF) classification was used to identify paired pathways with high cross-talk, and Monte Carlo cross-validation analysis was then repeated 50 times, to find the best paired pathways. During the analysis, all steps were repeated 50 times. After 50 runs, the top 10 paired pathways with the best AUC were extracted and were considered as significant paired pathways. These best paired pathways were tested with another independently published MM microarray data ([GSE85837](ncbi-geo:GSE85837){#ir0020}) using in silico validation.

2.1. Acquisition of gene expression profile {#s0015}
-------------------------------------------

The gene expression library of MM (accession number: [GSE6477](ncbi-geo:GSE6477){#ir0025}) [@bib14] was retrieved from Gene Expression Omnibus (GEO) database, based on the [GPL96](ncbi-geo:GPL96){#ir0030} platform of \[HG-U133A\]Affymetrix Human Genome U133A Array. There were 150 MM samples and 12 healthy donor plasma cell samples, in the [GSE6477](ncbi-geo:GSE6477){#ir0035} profile. The repeated probes were first eliminated, after obtaining the microarray profile. The remaining probes were then mapped to the genomics, to further obtain human gene symbols. Finally, 12,437 genes were identified for subsequent analysis.

2.2. DEGs identification {#s0020}
------------------------

During the research, "normalized quantile" was used to conduct normalization on mRNAs, with an average value determined across 162 samples [@bib15]. Genes with values greater than 0.25-fold quantile average across all samples were extracted. Compared to several other estimators, the quantile-adjusted conditional maximum likelihood (qCML) was the most reliable in terms of bias, on a wide range of conditions, and performed best in smaller samples with a common dispersion quotient [@bib16]. The qCML of edgeR package from Bioconductor was used to verify if these genes were expressed in a differential manner. Next, raw P values were corrected using a Benjamini-Hochberg method, based on a false discovery rate (FDR) [@bib17]. Genes were considered differentially expressed when FDR was less than 0.001 and \|log fold change (FC)\|was more than 2.

2.3. Pathway enrichment analysis {#s0025}
--------------------------------

Ingenuity pathways analysis (IPA), is widely utilized as a pathway database to analyze gene expression profile in the context of known biological responses and higher-order response pathways. In the present study, pathway enrichment analysis for DEGs was implemented using Fisher\'s exact test based on IPA tool, with the goal to extract significant pathways enriched by DEGs between MM and control samples. Hence, 589 biological pathways deposited in the IPA database were first downloaded. After the Fisher\'s exact test was applied to the genes in the IPA pathways and DEGs, the pathways enriched with P-value less than 0.01 were extracted. Later, the Benjamini-Hochberg procedure was used to correct the P values. Differential pathways were extracted based on the significance of FDR \< 0.05.

2.4. DS calculation for pathway cross-talk {#s0030}
------------------------------------------

DS is an index used to compare the expression levels in the subgroup of samples showing amplification and in samples without amplification [@bib18]. Thus, DS was employed to analyze the pathway cross-talk, in this paper. The DS was counted by comparing the gene expression levels of each paired pathway enriched by DEG in each sample, based on the description in the study by Cava et al. [@bib19]. Generally, DS score implicates the relationships between paired pathways, and a larger DS suggests higher difference of activity between pathways.

2.5. Extracting the best paired pathways {#s0035}
----------------------------------------

RF created by Breiman [@bib20], is a statistical method used to handle two issues of variable selection. To classify this methodology, an RF classification model was applied on the paired pathways based on the DS values of each sample. This helped to classify both MM and the control samples. AUC was calculated by a 10-fold cross-validation method, based on the following indexes: mtry and ntree. The mtry (the number of variables randomly sampled as candidates at each split) was equivalent to sqrt (p); p was the number of variables in the data matrix; and ntree (the number of trees grown) was equal to 500. All AUC values were then ranked in descending order, and the top 10 paired pathways were selected.

As documented in the validation analysis, the sample size in the training set was generally larger than that in the testing set. Of note, is the ratio of 6 to 4, which is a common distribution proportion. For example, Zhang et al. [@bib21] randomly selected 60% as the training set and the remaining 40% as the testing data. Thus, in this study, the Monte Carlo cross-validation method was employed to randomly select 60% of the original microarray data comprising of training data, and the remaining 40% was assigned to the testing data. This step was repeated 50 times, randomly forming new training and test datasets each time. For each bootstrap, DEGs and pathway enrichment analysis for DEGs, and a DS for the paired pathways was conducted. For each bootstrap, a training set was used to detect a DS for the top 10 paired pathways with the best AUC value between the two groups. For each bootstrap, a testing partition was employed to confirm the top 10 paired pathways. At the end of 50 runs, the list of the top 10 paired pathways sorted by descending rank were selected, such that each pathway pair was extracted in 50 bootstraps. Ultimately, the top 10 paired pathways ranked for all 50 runs, were regarded as significant.

2.6. In silico validation with independent MM microarray data {#s0040}
-------------------------------------------------------------

To predict these best paired pathways, other MM data of 15 patients with MM and 13 control patients, was obtained from the publicly available microarray dataset [GSE85837](ncbi-geo:GSE85837){#ir0040}. For validation, all steps and selection criteria were the same as the above analysis.

3. Results {#s0045}
==========

3.1. Identification of DEGs and pathway enrichment analysis {#s0050}
-----------------------------------------------------------

After normalization analysis, 1051 genes were obtained that had greater than 0.25-fold quantile average across all samples. From the differential expression analysis of MM and control samples, 60 DEGs with significance set as FDR \< 0.001 and \|log FC\| \> 2 (as shown in [Table 1](#t0005){ref-type="table"}) were identified. [Table 2](#t0010){ref-type="table"} displays 19 significant pathways enriched by DEGs, their FDR values, number of genes for each pathway, and the count of common genes between DEGs and genes in the pathways.Table 1List of differentially expressed genes (DEGs).Table 1**GenesLogFCFDRGenesLogFCFDR**RNASE2−4.26681.25E-24LMO2−2.024671.26E-04CLC−4.949291.05E-13CD24−2.245121.65E-04PRG3−3.908372.93E-12MRC1−2.063842.36E-04RNASE3−4.318715.08E-12CRISP3−2.731512.55E-04PRG2−5.934431.01E-09MS4A3−2.172142.61E-04MPO−2.524548.15E-09ZNF3582.0422132.66E-04DEFA4−2.223891.70E-08MS4A6A−2.215873.54E-04ELANE−4.398421.94E-08IL4R−2.13923.74E-04EPX−3.181139.02E-08PXDC1−2.085094.67E-04ARMC72.3141692.21E-07CD3202.2410424.83E-04CAMP−3.05499.82E-07CD163−2.526435.17E-04IGHG1−3.73072.23E-06LUM−3.582035.20E-04CTSH−2.878453.55E-06CXCL8−2.402435.26E-04AIF1−2.166564.43E-06NOD2−2.954535.26E-04LST1−2.192628.38E-06S100A8−2.703735.61E-04IGLJ3−4.491761.13E-05CXCL2−2.712295.61E-04CLPP2.321091.65E-05IGHD−4.070845.84E-04LTF−3.895541.65E-05HMOX1−2.368685.99E-04FABP4−2.795113.18E-05MS4A4A−3.381266.11E-04LYVE1−2.98193.18E-05HIF1A−2.131296.18E-04NRP1−2.081553.34E-05VNN2−2.40716.18E-04S100A12−2.163333.34E-05MAFB−3.45476.41E-04CEACAM8−3.527084.20E-05ALDH1A3−2.011856.80E-04IGLV1-44−4.84026.64E-05LHFP−2.189346.98E-04KCTD12−2.568916.99E-05S100A9−2.32738.20E-04CD14−3.155517.82E-05MNDA−3.148329.14E-04RPS112.0795628.44E-05HLA-DPA1−2.642839.63E-04IGK−3.997849.70E-05TGFBI−2.936609.89E-04P2RY13−2.466841.05E-04MAGEA42.3618719.92E-04DTX22.0714911.05E-04MROH7−2.036159.95E-04[^1]Table 2Pathways enriched by differentially expressed genes (DEGs).Table 2**PathwayFDRGenes in pathwayNumber of common genes**Granulocyte Adhesion and Diapedesis6.09E-111634EIF2 Signaling2.88E-101736Atherosclerosis Signaling1.32E-071191Hepatic Fibrosis / Hepatic Stellate Cell Activation1.66E-071372LXR/RXR Activation1.78E-071211T Helper Cell Differentiation2.91E-06623Bladder Cancer Signaling5.83E-06865Role of Macrophages2.23E-052824Complement System4.96E-05323Altered T Cell and B Cell Signaling in Rheumatoid Arthritis6.80E-05762IL-8 Signaling6.96E-051831PI3K Signaling in B Lymphocytes1.01E-041223Regulation of the Epithelial-Mesenchymal Transition Pathway1.17E-041751Neuroprotective Role of THOP1 in Alzheimer\'s Disease3.38E-04401Role of Osteoblasts5.18E-042142Acute Myeloid Leukemia Signaling5.48E-04763ILK Signaling7.71E-041812Macropinocytosis Signaling8.53E-04682LPS/IL-1 Mediated Inhibition of RXR Function9.14E-042102[^2]

3.2. Selection of best paired pathways {#s0055}
--------------------------------------

To evaluate the classification ability of this methodology, an RF model was used on the paired pathways to compute the AUC values based on the DS values, using a 10-fold cross-validation method. Each pathway was then sorted out based on its corresponding AUC values. A total of 32 paired pathways with AUC not less than 0.850 were identified. In literature, AUC greater than 0.7 is regarded as good, and an AUC of 1.0 denotes a perfect classification [@bib22]. Higher AUC values indicate good classification of disease, that is, higher AUC indicates a stronger pathway correlation with the disease. Thus, the focus was only on pathways with the 10 best AUC values, selected by Colaprico et al. [@bib23]. The top 10 paired pathways that had the best classification ability for MM and control samples for all 50 runs, are displayed in [Table 3](#t0015){ref-type="table"}. The paired pathways, inhibition of matrix metalloproteases and EIF2 signaling, obtained the best AUC value of 1.000. Moreover, the paired pathways of IL-8 signaling and EIF2 signaling also revealed good performance, with 0.975 AUC. Similar performance was found in the paired pathway of IL-8 signaling pathway and regulation of eIF4 and p70S6K signaling pathway with AUC of 0.939.Table 3Top 10 pairs of pathways with AUC value.Table 3Pairs of pathwaysAUC(1a) Inhibition of matrix metalloproteases1.000(1b) EIF2 signaling(2a) IL-8 signaling0.975(2b) EIF2 signaling(3a) IL-8 signaling0.939(3b) Regulation of eIF4 and p70S6K signaling(4a) IL-8 signaling0.927(4b) FGF signaling(5a) PI3K signaling in B lymphocytes0.910(5b) EIF2 signaling(6a) PI3K signaling in B lymphocytes0.900(6b) FGF signaling(7a) Colorectal cancer metastasis signaling0.898(7b) EIF2 signaling(8a) Altered T cell and B cell signaling in rheumatoid arthritis0.897(8b) EIF2 signaling(9a) Inhibition of matrix metalloproteases0.892(9b) Regulation of eIF4 and p70S6K signaling(10a) EIF2 signaling0.890(10b) TREM1 signaling[^3]

Following this, the top 10 paired pathways with occurrence frequency of not less than 5 in the 50 runs, were identified. Based on this result, it was found that the PI3K signaling pathway of B lymphocytes and EIF2 signaling pathway were involved in 27 bootstraps; the paired pathways (inhibition of matrix metalloproteases and EIF2 signaling) appeared in 10 runs, and the paired pathways (PI3K signaling in B lymphocytes; regulation of eIF4 and p70S6K signaling) existed in 10 bootstraps; and IL-8 signaling and EIF2 signaling pathways were involved in 7 runs. Specific information is shown in [Table 4](#t0020){ref-type="table"}.Table 4Top 10 pairs of pathways based on occurrence number not less than 5.Table 4**Pathway pairsTotal occurrence number**PI3K Signaling in B Lymphocytes; EIF2 Signaling27Inhibition of Matrix Metalloproteases; EIF2 Signaling10PI3K Signaling in B Lymphocytes; Regulation of eIF4 and p70S6K Signaling10Colorectal Cancer Metastasis Signaling; EIF2 Signaling8IL-8 Signaling; EIF2 Signaling7PI3K Signaling in B Lymphocytes; GABA Receptor Signaling7Role of NFAT in Regulation of the Immune Response; EIF2 Signaling6EIF2 Signaling; IL-17A Signaling in Fibroblasts6Granulocyte Adhesion and Diapedesis; EIF2 Signaling6Leukocyte Extravasation Signaling; EIF2 Signaling5EIF2 Signaling; IL-10 Signaling5MSP-RON Signaling Pathway; EIF2 Signaling5

3.3. In silico validation with independent MM microarray data {#s0060}
-------------------------------------------------------------

To validate the best paired pathways, independent MM data from the publicly available microarray dataset of [GSE85837](ncbi-geo:GSE85837){#ir0045}, was identified.

[Table 5](#t0025){ref-type="table"} shows the top 10 paired pathways with the best classification for MM and control samples for all 50 runs. The paired pathways, inhibition of matrix metalloproteases and EIF2 signaling pathways had the best AUC value of 0.971. Moreover, the paired TREM1 signaling and EIF2 signaling pathways also indicated high performance, with an AUC of 0.968. Similar performance levels were found in the paired IL-8 signaling and EIF2 signaling pathways, with an AUC of 0.961. These results further demonstrate that paired pathways are useful in diagnosing MM.Table 5Top 10 pairs of pathways with AUC value, validated using the other MM microarray data.Table 5Pairs of pathwaysAUC(1a) Inhibition of matrix metalloproteases0.971(1b) EIF2 signaling(2a) TREM1 signaling0.968(2b) EIF2 signaling(3a) EIF2 signaling0.961(3b) IL-8 signaling(4a) IL-10 signaling0.956(4b) EIF2 signaling(5a) Antigen Presentation Pathway0.955(5b) LPS/IL-1 Mediated Inhibition of RXR Function(6a) Caveolar-mediated Endocytosis Signaling0.955(6b) Agranulocyte Adhesion and Diapedesis(7a) Regulation of eIF4 and p70S6K Signaling0.953(7b) Actin Nucleation by ARP-WASP Complex(8a) Antigen Presentation Pathway0.947(8b) IL-6 Signaling(9a) PI3K Signaling in B Lymphocytes0.945(9b) GABA Receptor Signaling(10a) EIF2 Signaling0.944(10b) Actin Cytoskeleton Signaling[^4]

[Table 6](#t0030){ref-type="table"} shows the top 10 paired pathways with occurrence frequency ≥ 5 in the 50 runs. From this table, it can be seen that the paired pathways of caveolar-mediated endocytosis signaling and agranulocyte adhesion, as well as diapedesis were involved in 45 bootstraps. The paired pathways (inhibition of matrix metalloproteases and EIF2 signaling) appeared in 43 runs, and the paired pathways involved in 37 bootstraps were antigen presentation and IL-6 signaling pathways. Also, IL-8 signaling and EIF2 signaling pathways were involved in 31 runs. Significantly, based on the above results, it was observed that a total of 5 paired pathways were the common ones, which included EIF2 signaling/inhibition of matrix metalloproteases, EIF2 signaling/IL-8 signaling, EIF2 signaling/IL-17A signaling in fibroblasts, EIF2 signaling/IL-10 signaling, and PI3K signaling in B lymphocytes/GABA receptor signaling.Table 6Top 10 pairs of pathways based on occurrence number not less than 5, selected from the validated microarray data.Table 6**Pathway pairsTotal occurrence number**Caveolar-mediated Endocytosis Signaling; Agranulocyte Adhesion and Diapedesis45EIF2 Signaling; Inhibition of Matrix Metalloproteases43Antigen Presentation Pathway; IL-6 Signaling37EIF2 Signaling; IL-8 Signaling31EIF2 Signaling; Regulation of eIF4 and p70S6K Signaling31Antigen Presentation Pathway; LPS/IL-1 Mediated Inhibition of RXR Function21EIF2 Signaling; IL-17A Signaling in Fibroblasts11EIF2 Signaling; IL-10 Signaling9Regulation of eIF4 and p70S6K Signaling; Actin Nucleation by ARP-WASP Complex9PI3K Signaling in B Lymphocytes; GABA Receptor Signaling5

4. Discussion {#s0065}
=============

Pathway analysis has become the preferred approach to understand biological processes of genes, as this kind of analysis promotes scientific validity and explanation [@bib24]. Generally, different pathways involved in several biological processes act in a synergistic way. Extraction of pathway cross-talk makes data available to study pathway functions in greater detail, relative to single pathways [@bib25]. However, traditional pathway analysis methods mainly focus on individual dysregulated pathways, while pathway interactions are frequently not considered [@bib26]. Thus, in this paper, an integrative approach with Monte Carlo cross-validation analysis based on the DS values, was used to identify the best paired pathways that could distinguish MM from control samples. Ultimately, a total of 32 paired pathways with AUC not less than 0.850, among MM and control samples were identified. Nevertheless, only the top 10 paired pathways with higher AUC were focused on.

In this study, inhibition of matrix metalloproteases and EIF2 signaling pathways obtained the best AUC value of 1.000, with an occurrence frequency of 10, in analyzing [GSE6477](ncbi-geo:GSE6477){#ir0050}. In silico validation, inhibition of matrix metalloproteases and EIF2 signaling obtained the best AUC value of 0.971, with an occurrence frequency of 43. Matrix metalloproteinases, as a group of zinc-dependent endopeptidases involved in the degradation of extracellular matrix (ECM), exert important functions in tissue remodeling, and are connected with various physiological processes including migration, invasion, angiogenesis, and regulation of inflammatory processes [@bib27], [@bib28], [@bib29]. Angiogenesis and inflammation are the hallmarks of cancer [@bib30], [@bib31]. Moreover, suppressing matrix metalloproteases initially appeared to be a promising therapeutic approach for cancer [@bib32]. Significantly, the functions of matrix metalloproteases are influenced by reactive oxygen species (ROS). The inflammatory response at the tumor site creates large amounts of ROS that are produced by activated neutrophils and macrophages. Moreover, EIF2 alpha kinase has been indicated to control ROS levels [@bib33]. Hence, the cross-talk between inhibition of matrix metalloproteases and EIF2 signaling pathways may play a crucial role in the etiology of MM.

Another set of paired pathways, notably IL-8 signaling and EIF2 signaling pathways, were involved in this study for [GSE6477](ncbi-geo:GSE6477){#ir0055} in 7 runs, with an AUC of 0.975. In silico validation using [GSE85837](ncbi-geo:GSE85837){#ir0060}, IL-8 signaling and EIF2 signaling pathways were obtained, with an AUC value of 0.961 and an occurrence frequency of 31. As reported, multiple cytokines or chemokines, play an important role as mediators of paracrine signals between the tumor and multifarious components of the tumor microenvironment, which eventually results in tumor growth and progression [@bib34], [@bib35].

As a proinflammatory cytokine, IL-8 is a soluble mediator released by tumor cells that simultaneously exerts key functions in autocrine and paracrine modes in the tumor microenvironment. Significantly, in cancer tissues, tumor-derived IL-8 has been indicated to enhance tumor cell survival, proliferation, as well as migration based on autocrine activity, while inducing angiogenesis in endothelial cells due to paracrine activity [@bib36], [@bib37]. Moreover, there is significant epithelial--mesenchymal transition (EMT) during carcinoma progression [@bib38]. Of note, Romaine et al. [@bib39] have implicated that IL-8 signaling pathway is critical in the EMT process of human carcinoma cells. In addition, in MM patient plasma cells, IL-8 receptors (CXCR1 and CXCR2) were observed, and IL-8 parallel MM disease activity was related to bone marrow angiogenesis [@bib40]. Furthermore, EIF2 signaling pathway has been reported to mediate proinflammatory cytokine expression [@bib41]. Thus, it is speculated that the regulation of IL-8 and EIF2 signaling pathways may be important in the onset and progression of MM.

However, several limitations should be noted. To begin with, this study was a preliminary study of molecular mechanisms of MM. This work was conducted based on the bioinformatics approach, while the conclusions have not been verified using experiments. Further investigations are required to reveal changes in MM pathways, using animal experiments or patients' tissues.

In conclusion, this analysis sheds new light on the involvement of pathway cross-talk in the pathology of MM. However, the identified pathway cross-talk require more functional studies in later work.
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[^1]: FC, fold change; FDR, false discovery rate.

[^2]: FDR, false discovery rate; common gene, the overlap between DEGs and genes in the pathway.

[^3]: AUC, area under the curve.

[^4]: AUC, area under the curve.
